B. Klinger

发表

Modulation of IGF‐I receptors by exogenous hGH treatment in constitutionally short children

Z. Laron, R. Eshet, B. Klinger, 1993, Clinical endocrinology.

Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment.

Z. Laron, B. Klinger, Z. Laron,, 1993, Hormone research.

Opposing Effects of Growth Hormone and Insulin-like Growth Factor I on Serum Lipoprotein(a)

Z. Laron, Xingmin Wang, B. Klinger, 1997 .

Comparison of the growth‐promoting effects of insulin‐like growth factor I and growth hormone in the early years of life

Z. Laron, B. Klinger, Z. Laron,, 2000, Acta paediatrica.

Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance).

Z. Laron, B. Klinger, Z. Laron,, 1998, European journal of endocrinology.

Laron syndrome due to a post-receptor defect: response to IGF-I treatment.

A. Karasik, Z. Laron, R. Eshet, 1993, Israel journal of medical sciences.

Patients with Laron Syndrome Have Osteopenia/Osteoporosis

Z. Laron, B. Klinger, A. Silbergeld, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Serum prolactin in patients with Laron-type dwarfism: effect of insulin-like growth factor I.

Z. Laron, H. Schwartz, B. Klinger, 1992, Hormone research.

Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome.

D. Wilcken, Z. Laron, X. L. Wang, 1996, Metabolism: clinical and experimental.

Growth Hormone Treatment Increases Circulating Lipoprotein(a) in Children with Chronic Renal Failure

D. Wilcken, Z. Laron, X.-L. Wang, 1996, Journal of pediatric endocrinology & metabolism : JPEM.

Growth hormone therapy in normal short children induces a transitory decrease in plasma growth hormone releasing hormone levels and in human growth hormone responsiveness to exogenous growth hormone releasing hormone

Z. Laron, I. Gil-ad, A. Pertzelan, 1992, Journal of endocrinological investigation.

Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism.

Z. Laron, B. Klinger, A. Silbergeld, 1989, Acta endocrinologica.

Serum Insulin-like Growth Factor-I (IGF-I) Levels During Long-term IGF-I Treatment of Children and Adults with Primary GH Resistance (Laron Syndrome)

Z. Laron, B. Klinger, A. Silbergeld, 1999, Journal of pediatric endocrinology & metabolism : JPEM.

Up-regulation of insulin-like growth factor-I (IGF-I) receptor gene expression in patients with reduced serum IGF-I levels.

H. Werner, C. Roberts, D. Leroith, 1993, Journal of molecular endocrinology.

Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity.

A. Karasik, H. Kanety, Z. Laron, 1993, Acta endocrinologica.

Modulation of insulin like growth factor I (IGF-I) binding sites on erythrocytes by IGF-I treatment in patients with Laron syndrome (LS)

Z. Laron, R. Eshet, B. Klinger, 1993, Regulatory Peptides.

Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein.

R. Baxter, A. Karasik, H. Kanety, 1997, European journal of endocrinology.

IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF‐I

M. Ranke, Z. Laron, W. Blum, 1992, Clinical endocrinology.

Biochemical and hormonal changes induced by one week of administration of rIGF‐I to patients with Laron type dwarfism

Z. Laron, B. Klinger, B. Erster, 1991, Clinical endocrinology.

Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH.

Z. Laron, I. Gil-ad, R. Lewin, 1990, Acta endocrinologica.

EFFECT OF ACUTE ADMINISTRATION OF INSULIN-LIKE GROWTH FACTOR I IN PATIENTS WITH LARON-TYPE DWARFISM

Z. Laron, B. Klinger, B. Erster, 1988, The Lancet.

Insulin‐like growth factor‐I raises serum procollagen levels in children and adults with Laron syndrome

Z. Laron, B. Klinger, A. Silbergeld, 1996, Clinical endocrinology.

Effect of insulin-like growth factor I on the thyroid axis in patients with Laron-type dwarfism and healthy subjects.

Z. Laron, B. Klinger, S. Anin, 1992, Acta endocrinologica.

Growth curves for Laron syndrome.

Z. Laron, P. Lilos, B. Klinger, 1993, Archives of disease in childhood.

Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment.

Z. Laron, Y. Avitzur, B. Klinger, 1995, Metabolism: clinical and experimental.

Growth During and 2 Years After Stopping GH Treatment in Prepubertal Children with Idiopathic Short Stature

Z. Laron, P. Lilos, A. Pertzelan, 1997, Journal of pediatric endocrinology & metabolism : JPEM.

IGF-I treatment of adult patients with Laron syndrome: preliminary results.

Z. Laron, B. Klinger, 1994, Clinical endocrinology.

Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism

Z. Laron, Y. Klipper-Aurbach, B. Klinger, 1992, The Lancet.

Renal function in Laron syndrome patients treated by insulin-like growth factor-I

Z. Laron, B. Klinger, Z. Laron,, 1994, Pediatric Nephrology.

Intranasal administration of the GHRP hexarelin accelerates growth in short children

Z. Laron, B. Klinger, S. Anin, 1995, Clinical endocrinology.

Three Year IGF-I Treatment of Children with Laron Syndrome

Z. Laron, B. Klinger, Z. Laron,, 1995, Journal of pediatric endocrinology & metabolism : JPEM.

Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)

D. Wilcken, Z. Laron, X. L. Wang, 1997, European journal of endocrinology.

Elimination characteristics of intravenously administered rIGF-I in Laron-type dwarfs.

Z. Laron, M. Garty, B. Klinger, 1990, Developmental Pharmacology and Therapeutics.

Intronic Mutation in the Growth Hormone (GH) Receptor Gene from a Girl with Laron Syndrome and Extremely High Serum GH Binding Protein: Extended Phenotypic Study in a Very Large Pedigree

S. Amselem, H. Kanety, R. Eshet, 1997, Journal of pediatric endocrinology & metabolism : JPEM.

Insulin Resistance in Laron Syndrome (Primary Insulin-like Growth Factor-I (IGF-I) Deficiency) and Effect of IGF-I Replacement Therapy

Z. Laron, Y. Avitzur, B. Klinger, 1997 .

Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron syndrome.

O. Brat, I. Ziv, M. Avraham, 1997, Hormone research.

IGF‐I treatment of adult patients with Laron syndrome: preliminary results

B. Klinger, Z. Laron,, 1994 .

Growth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature.

V. Koivisto, A. Pertzelan, A. Suikkari, 1992, Acta endocrinologica.

Laron syndrome: clinical features, molecular pathology and treatment.

B. Klinger, Z. Laron,, 1994, Hormone research.

Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin)

R. Deghenghi, F. Boutignon, E. Lubin, 1994, Clinical endocrinology.

Picture of the month. Laron-type dwarfism.

M. Feingold, M. Grunebaum, B. Klinger, 1991, American journal of diseases of children.

Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children.

B. Klinger, A. Silbergeld, J. Frenkel, 1996, European journal of endocrinology.